Abstract
Objectives: People with cystic fibrosis (CF) are at risk of fat-soluble vitamin deficiency due to pancreatic insufficiency. Routine supplementation and monitoring of fat-soluble vitamin levels are undertaken. Studies show ivacaftor improves pancreatic function, and it is expected that elexacaftor/tezacaftor/ivacaftor (ETI) has similar effects. This study aimed to assess changes in fat-soluble vitamin levels in children starting ETI therapy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Paper Title
Journal
Date
